| |
|
|
|
Rheumatoid Arthritis: Treatment
Description: A chronic, disabling condition, rheumatoid arthritis (RA) can cause joint pain and deformity. Characterized by chronic inflammation, experts believe that an autoimmune disorder causes RA. It strikes during productive adult years, between the ages of 20 and 65, with median onset at age 50. This course describes the options available for treating rheumatoid arthritis.
|
COURSE OUTLINE
INTRODUCTION
1. Course Information
2. Interface Tour
3. Course Overview
PROGNOSIS
4. Objectives
5. Disease Course
6. Monitoring Progression of RA
7. Molecular Markers of Pathogenesis
8. Progress Check
TREATMENT
9. Objectives
10. General Approaches and Recommendations
11. Analgesics
12. Traditional NSAIDs
13. Selective COX-2 Inhibitors
14. Corticosteroids
15. DMARDS: Methotrexate
16. DMARDS: Hydroxychloroquine
17. DMARDS: Sulphasalazine
18. DMARDS: Cyclosporine
19. DMARDS:Leflunomide
20. Older DMARDs
21. Cytotoxic Agents
22. Biologic Agents: TNF-alpha Inhibitors
23. Biologic Agents: Etanercept
24. Biologic Agents: Infliximab and Adalimumab
25. Biologic Agents: Anakinra
26. Non-pharmacologic Treatments
27. Progress Check
CONCLUSION
28. Summary
|
|
COURSE OBJECTIVES
Students completing this course should be able
to:
- Describe rheumatoid arthritis progression.
- Explain RA's extra-articular and systemic manifestations
- Describe the histological changes caused by rheumatoid arthritis progression and how physicians monitor tissue damage
- Identify rheumatoid arthritis activity and progression molecular markers
- Describe the general approaches in rheumatoid arthritis treatment
- Explain therapy goals, guidelines and treatment recommendations
- Describe the mechanism of action, efficacy, adverse reactions, and other features of the different rheumatoid arthritis treatments
- Explain the advantages and disadvantages of non-pharmacological treatment strategies for rheumatoid arthritis
|
|
|
|
 SeerPharma has partnered with GeneEd to now distribute courses in Major Therapeutic Areas, Clinical Research, and Biotechnology & Genetics.
|
|